# The Pharmacokinetics of GLA5PR Tablet According to the Renal Function

> **NCT03963362** · PHASE1 · UNKNOWN · sponsor: **GL Pharm Tech Corporation** · enrollment: 24 (estimated)

## Conditions studied

- Neuropathic Pain

## Interventions

- **DRUG:** GLA5PR tablet 75 mg
- **DRUG:** GLA5PR tablet 150 mg

## Key facts

- **NCT ID:** NCT03963362
- **Lead sponsor:** GL Pharm Tech Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-17
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-06-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2020-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03963362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03963362, "The Pharmacokinetics of GLA5PR Tablet According to the Renal Function". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03963362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*